Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002
Launched by ESPERION THERAPEUTICS, INC. · Jan 22, 2014
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy Male Volunteers
- • BMI 10-35 kg/m2
- Exclusion Criteria:
- • Hx of CV, renal, hepatic, chronic respiratory or GI disease
- • Hx of drug or alcohol abuse
- • smoking within 12 mos of screening
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with cardiovascular diseases. With a focus on addressing unmet medical needs, Esperion specializes in lipid management and the reduction of cardiovascular risk, leveraging its expertise in drug development to bring novel treatments to market. The company's commitment to advancing science is reflected in its robust pipeline of therapies aimed at improving patient outcomes and enhancing quality of life. Through strategic collaborations and a patient-centered approach, Esperion strives to redefine the future of cardiovascular care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, , United Kingdom
Patients applied
Trial Officials
Stuart Mair, MBChB, DRCOG, DCPSA, MFPM
Principal Investigator
Quotient Clinical, Mere Way, Ruddington Fields, Ruddington, Nottinham NG11 6JS, UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials